Abstract:Theranostics with radioligands (radiotheranostics) has played a pivotal role in oncology. Radiotheranostics explores the molecular targets expressed on tumor cells to target them for imaging and therapy. In this way, radiotheranostics entails non-invasive demonstration of the in vivo expression of a molecular target of interest through imaging followed by the administration of therapeutic radioligand targeting the tumor-expressed molecular target. Therefore, radiotheranostics ensures that only patients with a high likelihood of response are treated with a particular radiotheranostic agent, ensuring the delivery of personalized care to cancer patients. Within the last decades, a couple of radiotheranostics agents, including Lutetium-177 DOTATATE ( 177 Lu-DOTATATE) and Lutetium-177 prostate-specific membrane antigen ( 177 Lu-PSMA), were shown to prolong the survival of cancer patients compared to the current standard of care leading to the regulatory approval of these agents for routine use in oncology care. This recent string of successful approvals has broadened the interest in the development of different radiotheranostic agents and their investigation for clinical translation. In this work, we present an updated appraisal of the literature, reviewing the recent advances in the use of established radiotheranostic agents such as radioiodine for differentiated thyroid carcinoma and Iodine-131-labeled meta-iodobenzylguanidine therapy of tumors of the sympathoadrenal axis as well as the recently approved 177 Lu-DOTATATE and 177 Lu-PSMA for differentiated neuroendocrine tumors and advanced prostate cancer, respectively. We also discuss the radiotheranostic agents that have been comprehensively characterized in preclinical studies and have shown some clinical evidence supporting their safety and efficacy, especially those targeting fibroblast activation protein (FAP) and chemokine receptor 4 (CXCR4) and those still being investigated in preclinical studies such as those targeting poly (ADP-ribose) polymerase (PARP) and epidermal growth factor receptor 2.

A review on 90Y-labeled compounds and biomolecules

Radiolabeling of bionanomaterials with technetium 99m: current state and future prospects

Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine

Radioligand Therapy in Lymphoma: Past, Present, and Future

Design and Application of Nuclear and Molecular Theragnostic Probes

The Development and Application of Tritium-Labeled Compounds in Biomedical Research

Site-specific bioconjugation and nuclear imaging

An Overview of Structural Framework and Classification of Theranostic Radiopharmaceuticals

Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation

Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects

A Brief Review of Radiolabelling Nucleic Acid‐Based Molecules for Tracking and Monitoring

Molecular Imaging and Therapy of Cancer with Radiolabeled Nanoparticles.

Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics

Nano-radiopharmaceuticals as therapeutic agents

A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer

Application of Technetium 99 Metastable Radioactive Nanosystems: Nanoparticles, Liposomes, and Nanoemulsion for Biomedical Application

Potential Theranostic Boron Neutron Capture Therapy Agents as Multimodal Radiopharmaceuticals

Recent Advances in 18F-Labeled Amino Acids Synthesis and Application

Advances in Radioligand Theranostics in Oncology

Effect of Polymer and Cell Membrane Coatings on Theranostic Applications of Nanoparticles: A Review

Nuclear Medicine: the Synergy of Radiochemistry and Molecular Medicine